Eye Health News and Research

Latest Eye Health News and Research

Long-term use of reverse geometry lenses may induce inflammatory response

Continuous long-term overnight use of reverse geometry lenses results in a significantly increased presence of inflammatory mediators compared with wearing 30-night silicone-hydrogel contact lenses or wearing no lenses, show study results.

27 Jul 2012

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Horizon Pharma, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved RAYOS (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD).

26 Jul 2012

Insomnia: an interview with Dr Darryle Schoepp

Insomnia is a very common disorder. In medical terms it can affect a third of people. It affects elderly as well as non-elderly people, and is more common in women.

26 Jul 2012

AIDS 2012 plenary speakers call for innovative financing, continued research for HIV cure

Speakers at Tuesday's plenary session at the XIX International AIDS Conference in Washington, D.C. highlighted the challenges that lie ahead in the response to HIV/AIDS and discussed potential solutions, ABC News reports.

26 Jul 2012

Obama skipping AIDS conference; Black community still bearing high burden of the disease

For all the dignitaries on the schedule at the International AIDS Conference this week in Washington, including Secretary of State Hillary Clinton, Microsoft Corp. co-founder Bill Gates and former President Bill Clinton, it's the absence of one that has activists talking. With the conference being held in the U.S. for the first time in 22 years, President Barack Obama is out of town campaigning and raising money for his re-election. His only presence is a 50-second cameo in a three-minute video welcoming delegates.

26 Jul 2012

Assistant Sec. of Health Koh addresses AIDS 2012 plenary; HHS Sec. Sebelius speaks at Washington Post event

Speaking at the plenary session of the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., on Monday, U.S. Assistant Secretary for Health Howard Koh discussed the development and implementation of the United States' first-ever comprehensive National HIV/AIDS Strategy, ABC News reports.

26 Jul 2012

AAQ chemical temporarily restores vision in blind mice

A team of University of California, Berkeley, scientists in collaboration with researchers at the University of Munich and University of Washington in Seattle has discovered a chemical that temporarily restores some vision to blind mice, and is working on an improved compound that may someday allow people with degenerative blindness to see again.

26 Jul 2012

AHAF announces glaucoma and macular degeneration research grants

The American Health Assistance Foundation, a nonprofit organization with a history of funding breakthrough research on age-related vision diseases, announced today that it has awarded 21 new grants totaling $2.1 million to scientists worldwide who are studying glaucoma and macular degeneration. The two conditions are the leading causes of irreversible blindness in the world.

26 Jul 2012

Early-age cataract surgery increases central corneal thickness

When congenital cataract surgery is performed at an early age, central corneal thickness increases, show study results published in the British Journal of Ophthalmology.

25 Jul 2012

Microneedles can deliver drug formulations into the eye

Thanks to tiny microneedles, eye doctors may soon have a better way to treat diseases such as macular degeneration that affect tissues in the back of the eye. That could be important as the population ages and develops more eye-related illnesses - and as pharmaceutical companies develop new drugs that otherwise could only be administered by injecting into the eye with a hypodermic needle.

24 Jul 2012

Ocular Therapeutix announces results from sustained release OTX-TP1 study on glaucoma

Ocular Therapeutix, Inc. announced today initial results of their sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma. This travoprost punctum plug (OTX-TP1) was evaluated for the reduction of elevated intraocular pressure in subjects with open-angle glaucoma or ocular hypertension over a 30 day period.

24 Jul 2012

FDA approves Forest Laboratories’ Tudorza Pressair to treat COPD

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) has approved Tudorza Pressair (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Forest Pharmaceuticals receives FDA approval for Tudorza Pressair to treat COPD

The U.S. Food and Drug Administration today approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Tiny microneedles to treat macular degeneration

23 Jul 2012

Insights on neural mechanisms behind guidance of attention

Ever wonder how the human brain, which is constantly bombarded with millions of pieces of visual information, can filter out what's unimportant and focus on what's most useful?

23 Jul 2012

Noted philanthropist to launch mobile eye clinic in North India

Noted entrepreneur and philanthropist, Tej Kohli is all set to launch Drishti Rath, a complete eye clinic on wheels. After the successful launch of the corneal blindness eradication programme in 2010, which enabled hundreds of poverty stricken corneal blind to get vision and which is still running successfully across NCR and neighbouring rural areas, Tej is set to launch this first-of-its-kind initiative in North India.

23 Jul 2012

Foundation Fighting Blindness grants US$125,000 to Oxford BioMedica for UshStat Phase I/IIa trial

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical Research Institute (FFBCRI) formerly known as the National Neurovision Research Institute (NNRI).

23 Jul 2012

BioDiem presents positive findings of their eye disease drug at international conference

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.

22 Jul 2012

State roundup: Texas Medicaid fraud probes use controversial tool

When it comes to finding cost savings in the state's unwieldy Medicaid program, the Health and Human Services Commission's Office of Inspector General gets high marks. … But OIG's dollar-recovery strategy -- which includes an increased reliance on a rule that allows investigators to freeze financing for any health provider accused of overbilling -- has enraged doctors, dentists and other providers who treat Medicaid patients.

21 Jul 2012

Second Sight’s Argus II Retinal Prosthesis System scheduled for FDA panel review

Second Sight Medical Products Inc., the world's leading developer and manufacturer of retinal prostheses, today announced that a U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel has been scheduled to review the data presented in the company's Humanitarian Device Exemption (HDE) market approval application for its Argus II Retinal Prosthesis System (Argus II prosthesis) on September 28, 2012 in Gaithersburg, Maryland.

21 Jul 2012